Pathophysiologic therapeutic targets in hypertension: a cardiological point of view

Bibliography

• Tang WHW. Metabolic approach in heart failure. Rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 2006;48:999-1000
   PubMedGoogle Scholar
• Morganti A. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes. J Am Soc Nephrol 2006;17:S141-4
   PubMed Web of Science ®Google Scholar
• Mancia G, Dell'Oro R, Quarti-Trevano F, Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 2006;24:S51-6
   Google Scholar
• Laragh JH, Sealey JE. Renin angiotensin aldosterone system and the renal regulation of sodium, potassium, and blood pressure homeostasis. In: Windhager EE, editor. Handblock of Physiology, Section 8, Renal physiology. Oxford University Press; New York: 1991. p. 1409-541
   Google Scholar
• Mendlowitz M, Gitlow SE, Wolf RL, Naftchi NE. Mechanisms in essential hypertension. Dis Chest 1964;45:360-4
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Bennett WM, McDonald WJ, Kuehnel E, Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977;22:499-504
   PubMed Web of Science ®Google Scholar
• Freis ED. How diuretics lower blood pressure. Am Heart J 1983;106:185-7
   PubMed Web of Science ®Google Scholar
• Insel PA, Motulsky HJ. A hypothesis linking intracellular sodium, membrane receptors, and hypertension. Life Sci 1984;34:1009-13
   PubMed Web of Science ®Google Scholar
• Davis BR, Cutler JA, Gordon DJ, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Research Group. Am J Hypertens 1996;9:342-60
   PubMed Web of Science ®Google Scholar
• ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial l (ALLHAT). JAMA 2000;283:1967-75
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Einhorn PT, Davis BR, Massie BM, The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis. Am Heart J 2007;153:42-53
   PubMedGoogle Scholar
• Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol 2001;38:1295-6
   PubMed Web of Science ®Google Scholar
• Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 2003;5:9-13
   Google Scholar
• Wing LM, Reid CM, Ryan P, A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92
   PubMed Web of Science ®Google Scholar
• Bohlen HG. Localization of vascular resistance changes during hypertension. Hypertension 1986;8:181-3
   PubMed Web of Science ®Google Scholar
• Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-30
   PubMed Web of Science ®Google Scholar
• Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008;26:494-500
   PubMed Web of Science ®Google Scholar
• Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9
   PubMed Web of Science ®Google Scholar
• Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67:26B-35B
   Google Scholar
• Eriksson JW, Jansson PA, Carlberg B, Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008;52:1030-7
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J, Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-scandinavian cardiac outcomes trial–blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
   PubMed Web of Science ®Google Scholar
• Shafi T, Appel LJ, Miller ER III, Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008;52:1022-9
   PubMed Web of Science ®Google Scholar
• Reungjui S, Pratipanawatr T, Johnson RJ, Nakagawa T. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 2008;17:470-6
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000;18:1149-54
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Dell'Oro R, Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-9
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992;13:G28-33
   PubMedGoogle Scholar
• Whelton P, Barzilay J, Cushman WC, Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, For the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12
   PubMed Web of Science ®Google Scholar
• Kostis JB, Wilson AC, Freudenberger RS, SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35
   PubMed Web of Science ®Google Scholar
• Fonseca FA, Ihara SS, Izar MC, Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 2003;30:779-85
   PubMedGoogle Scholar
• Carter BL, Einhorn PT, Brands M, Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 2008;52:30-6
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Oberman A, Blaufox MD, The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992;5:37-44
   PubMed Web of Science ®Google Scholar
• Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001;21:676-83
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
   PubMed Web of Science ®Google Scholar
• Bradley HA, Wiysonge CS, Volmink JA, How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24:2131-41
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley H, Mayosi BM, Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;1:CD002003
   PubMedGoogle Scholar
• Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker–induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9
   PubMed Web of Science ®Google Scholar
• Fragasso G, Cera M, Margonato A. Different metabolic effects of selective and non-selective beta-blockers rather than mere heart rate reduction may be the mechanism by which beta-blockade prevents cardiovascular events. J Am Coll Cardiol 2009;53:2105
   PubMedGoogle Scholar
• Williams B, Lacy PS, Thom SM, Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
   PubMed Web of Science ®Google Scholar
• Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23
   PubMed Web of Science ®Google Scholar
• Ram CV. Beta-blockers in hypertension. Am J Cardiol 2010;106:1819-25
   PubMed Web of Science ®Google Scholar
• Weidmann P, Beretta-Piccoli C, Ziegler W, Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension. Klin Wochenschr 1976;54:765-73
   PubMedGoogle Scholar
• Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade. Circ Res 1983;53:389-400
   PubMedGoogle Scholar
• Taddei S, Virdis A, Ghiadoni L, Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001;19:1379-86
   PubMed Web of Science ®Google Scholar
• Schiffrin LE, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996;14:1247-55
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Buzzigoli G, Bonadonna R, Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7
   PubMed Web of Science ®Google Scholar
• Piatti PM, Monti LD, Galli L, Relationship between endothelin-1 concentrations and metabolic alterations typical of the Insulin Resistance Syndrome. Metabolism 2000;49:748-52
   PubMed Web of Science ®Google Scholar
• Eliasson K, Lins LE, Rossner S. Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 1981;20:335-8
   PubMedGoogle Scholar
• Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-52
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
   PubMed Web of Science ®Google Scholar
• Rizos E, Bairaktari E, Kostoula A, The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003;8:127-34
   PubMedGoogle Scholar
• Kaiser T, Heise T, Nosek L, Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006;24:1397-403
   PubMed Web of Science ®Google Scholar
• Celik T, Iyisoy A, Kursaklioglu H, Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6
   PubMed Web of Science ®Google Scholar
• Mason RP, Kalinowski L, Jacob RF, Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801
   PubMed Web of Science ®Google Scholar
• Pasini AF, Garbin U, Stranieri C, Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44
   PubMed Web of Science ®Google Scholar
• Greenland P, Daviglus ML, Dyer AR, Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago heart association detection project in industry. Am J Epidemiol 1999;149:853-62
   PubMed Web of Science ®Google Scholar
• Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997;18:1404-10
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21
   PubMed Web of Science ®Google Scholar
• Balansard P, Chabrillat Y, Paulin R, Effect of atenolol, a new cardioselective beta-blocker, on plasma renin activity in treatment of hypertension. Acta Cardiol 1977;32:229-43
   PubMedGoogle Scholar
• Fagard R, Amery A, Deplaen JF, Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol. Clin Sci Mol Med Suppl 1976;3:215s-7s
   Google Scholar
• Ishizaki T, Oyama Y, Suganuma T, A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. Br J Clin Pharmacol 1983;16:17-25
   PubMed Web of Science ®Google Scholar
• Pitkajarvi T, Ylitalo P, Metsa-Ketela T, Vapaatalo H. The effects of a beta1-blocking agent, atenolol, on blood pressure, plasma renin activity and prostaglandin F2alpha excretion in patients with essential hypertension. Acta Med Scand 1979;206:107-13
   PubMed Web of Science ®Google Scholar
• Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988;1:91-6
   PubMed Web of Science ®Google Scholar
• Beto JA, Bansal VK. Quality of life in treatment of hypertension. Am J Hypertens 1992;5:125-33
   PubMed Web of Science ®Google Scholar
• Kendall MJ. Pharmacology of third generation beta blockers: greater benefits, fewer risks. J Cardiovasc Pharmacol 1989;14:S4-8
   Google Scholar
• Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005;46:637-42
   PubMed Web of Science ®Google Scholar
• Hamada T, Watanabe M, Kaneda T, Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998;16:111-18
   PubMed Web of Science ®Google Scholar
• Bonadue D, Petretta M, Ianniciello A, Comparison of verapamil versus felodipine on heart rate variability after acute myocardial infarction. Am J Cardiol 1997;79:564-9
   PubMedGoogle Scholar
• Kailasam MT, Parmer RJ, Cervenka JH, Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-9
   PubMedGoogle Scholar
• Vaage-Nilsen M, Rasmussen V. Effect of Verapamil on heart rate variability after an acute myocardial infarction. Cardiovasc Drugs Ther 1998;12:285-90
   PubMed Web of Science ®Google Scholar
• Staszewska-Woolley J. Modification by diltiazem, a calcium antagonist, of the pulmonary vagal and cardiac sympathetic chemoreflexes in the dog. Clin Exp Pharmacol Physiol 1987;14:455-64
   PubMedGoogle Scholar
• Giudicelli JF, Berdeaux A, Edouard A, Attenuation by diltiazem of arterial baroreflex sensitivity in man. Eur J Clin Pharmacol 1984;26:675-9
   PubMedGoogle Scholar
• Psaty BM, Smith NL, Siscovick DS, Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? Herz 1995;20:365-9
   PubMedGoogle Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
   PubMed Web of Science ®Google Scholar
• Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996;275:423-4
   PubMed Web of Science ®Google Scholar
• Pahor M, Psaty BM, Alderman MH, Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54
   PubMed Web of Science ®Google Scholar
• Shibata MC, Leon H, Chatterley T, Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Am J Cardiol 2010;106:228-35
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI). Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:1-290
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982;307:1618-27
   PubMed Web of Science ®Google Scholar
• Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985;249:F619-29
   PubMed Web of Science ®Google Scholar
• Chellingsworth MC, Kendall MJ, Lote CJ, Thewles A. Diuresis and natriuresis after dihydropyridines: role of prostaglandin E. J Hum Hypertens 1990;4:241-5
   PubMedGoogle Scholar
• Madeddu P, Oppes M, Soro A, Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system. J Cardiovasc Pharmacol 1987;9:536-40
   PubMedGoogle Scholar
• Kaplan NM. Calcium entry blockers in the treatment of hypertension: current status and future prospects. JAMA 1989;262:817-23
   PubMed Web of Science ®Google Scholar
• Epstein M, De Micheli AG. Natriuretic effects of calcium antagonists. In: Epstein M, editor. Calcium antagonists in clinical medicine. Hanley and Belfus; Philadelphia: 1992. p. 349-66
   Google Scholar
• Ene MD, Williamson PJ, Roberts CJC, Waddell G. The natriuresis following oral administration of the calcium antagonists-nifedipine and nitrendipine. Br J Clin Pharmacol 1985;19:423-7
   PubMedGoogle Scholar
• Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-73
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
   PubMed Web of Science ®Google Scholar
• Bakris GL, Copley JB, Vicknair N, Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, Secic M, Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002
   PubMed Web of Science ®Google Scholar
• Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998;54:889-96
   PubMed Web of Science ®Google Scholar
• Salomone S, Silva LM, Morel N, Godfraind T. Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol 1996;354:505-12
   PubMed Web of Science ®Google Scholar
• Salomone S, Morel N, Godfraind T. Effects of 8-bromocyclic GMP and verapamil on depolarization-evoked Ca2+ signal and contraction in rat aorta. Br J Pharmacol 1995;114:1731-7
   PubMedGoogle Scholar
• Godfraind D, Salomone S. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 1996;10:439-46
   PubMed Web of Science ®Google Scholar
• Huang S, Simonson MS, Dunn MJ. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J 1993;125:589-97
   PubMedGoogle Scholar
• Muiesan G, Agabiti-Rosei E, Romanelli G, Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986;57:44D-9D
   PubMedGoogle Scholar
• Agabiti-Rosei E, Muiesan ML, Romanelli G, Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol 1986;7:916-24
   PubMedGoogle Scholar
• Epstein M. Calcium channel blockers and hypertension: evolving perspective–1996. Cardiovasc Drugs Ther 1997;10:883-91
   PubMedGoogle Scholar
• Hossack KF, Brown BG, Stewart DK, Dodge HT. Diltiazem-induced blockade of sympathetically mediated constriction of normal and diseased coronary arteries: lack of epicardial coronary dilatory effect in humans. Circulation 1984;70:465-71
   PubMedGoogle Scholar
• Papavassiliou MV, Vyssoulis GP, Karpanou EA, Toutouzas PK Side effects of antihypertensive treatment with calcium channel antagonists. Am J Hypertens 2001;14:114A
   PubMed Web of Science ®Google Scholar
• Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens 2003;5:330-5
   PubMedGoogle Scholar
• Fletcher AE, Chester PC, Hawkins CM, The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989;3:125-30
   PubMed Web of Science ®Google Scholar
• Castro-Chaves P, Cerqueira R, Pintalhao M, Leite-Moreira AF. New pathways of the renin–angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Expert Opin Ther Targets 2010;14:485-96
   PubMed Web of Science ®Google Scholar
• Brunner HR, Sealey JE, Laragh JH. Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics. Circ Res 1973;32:99-105
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Hannedouche T, Landais P, Goldfarb B, Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994;309:833-7
   PubMedGoogle Scholar
• Abdulla J, Barlera S, Latini R, A systematic review: effect of angiotensin converting enzyme-inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007;9:129-35
   PubMedGoogle Scholar
• HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Sanchez RA, Marco E, Gilbert HB, Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 1985;30(Suppl 1):49-58
   PubMedGoogle Scholar
• Atlas SA, Case DB, Sealey JE, Laragh JH. McKinstry DN.Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979;1:274-80
   PubMed Web of Science ®Google Scholar
• De Gennaro Colonna V, Rigamonti A, Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in l-NAME-induced hypertensive rats. Eur J Pharmacol 2005;516:253-9
   PubMedGoogle Scholar
• Imai Y, Abe K, Seino M, Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. Am J Cardiol 1982;49:1537-9
   PubMedGoogle Scholar
• Sasaki J, Arakawa K. Effect of captopril on high-density lipoprotein subfractions in patients with mild to moderate essential hypertension. Clin Ther 1989;11:129-34
   PubMedGoogle Scholar
• Paolisso G, Gambardella A, Verza M, ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992;6:175-9
   PubMed Web of Science ®Google Scholar
• Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99:1006-12
   PubMed Web of Science ®Google Scholar
• Croog SH, Levine S, Testa MA, The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64
   PubMed Web of Science ®Google Scholar
• Israeli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy; a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
   PubMed Web of Science ®Google Scholar
• Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of Angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011;4:685-91
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7:933-6
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH, ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the international society for heart and lung transplantation endorsed by the heart failure society of America. JACC 2001;38:2101-13
   Google Scholar
• Ruilope LM. Valsartan and the kidney: review of preclinical and clinical data. Adv Ther 2001;18:57-66
   PubMedGoogle Scholar
• Abassi ZA, Kelly G, Golomb E, Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther 1994;268:224-30
   PubMed Web of Science ®Google Scholar
• Fukuda M, Yamanaka T, Mizuno M, Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008;26:583-8
   PubMed Web of Science ®Google Scholar
• Huang BS, Ahmad M, Tan J, Leenen FH. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 2007;43:479-86
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Hermann F, Wiesli P, Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007;25:785-91
   PubMed Web of Science ®Google Scholar
• Naya M, Tsukamoto T, Morita K, Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-9
   PubMed Web of Science ®Google Scholar
• Kintscher U, Bramlage P, Paar WD, Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a subanalysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007;6:12
   PubMed Web of Science ®Google Scholar
• Vitale C, Mercuro G, Castiglioni C, Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Seljeflot I, Torjesen PA, Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007;56:1470-7
   PubMed Web of Science ®Google Scholar
• Nishimura H, Sanaka T, Tanihata Y, Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008;31:1611-18
   PubMed Web of Science ®Google Scholar
• Sanchez RA, Masnatta LD, Pesiney C, Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008;26:2393-8
   PubMedGoogle Scholar
• Karagiannis A, Mikhailidis DP, Athyros VG, The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007;11:191-205
   PubMed Web of Science ®Google Scholar
• Matchar DB, McCrory DC, Orlando LA, Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29
   PubMed Web of Science ®Google Scholar
• Sipahi I, Debanne SM, Rowland DY, Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-36
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Neutel JM, Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens 2003;5:322-9
   PubMedGoogle Scholar
• Volpe M, Ruilope LM, McInnes GT, Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005;19:331-9
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006;8:E146-52
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study. Lancet 1999;354:1751-6
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L, Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16
   PubMed Web of Science ®Google Scholar
• VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMedGoogle Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Ueda S. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-Receptor Blockers - Questions Remain Unsolved. J Pharmacol Sci 2010;113:292-5
   PubMedGoogle Scholar
• Volpe M, Tocci G. Managing hypertension in cardiology practice according to risk profile. Int J Clin Pract 2008;62:1403-12
   PubMedGoogle Scholar
• Hansson L, Hedner T, Lund-Johansen P, Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Rosei EA, Dal Palu C, The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667-76
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G, CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
   PubMed Web of Science ®Google Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Goerdt CJ, Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressare. Hypertension 2006;47:352-8
   PubMed Web of Science ®Google Scholar
• Maseri A. Viewpoint. Circulation 2006;113:f29-30
   Google Scholar
• Whittington CJ, Kendall T, Fonagy P, Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5
   PubMed Web of Science ®Google Scholar